Citations

Showing 10 of 108081 citations.

Immunotherapy in lymphoma
Ansell, Stephen M. , Caligaris‐Cappio, Federico , Maloney, David G.

Mayo Clinic

Hematological Oncology | June 7, 2017 | Volume: 35 | Issue: S1 | Pages: 88-91

10.1002/hon.2408 | PMID 28591421 Get It

Impact of concomitant dexamethasone dosing schedule on bortezomib‐induced peripheral neuropathy in multiple myeloma
Kumar, Shaji , Laubach, Jacob P. , Giove, Thomas J., Quick, Maureen, Neuwirth, Rachel, Yung, Godwin , Richardson, Paul G. , Kumar, Shaji K , Rajkumar, S. Vincent , Richardson, Paul Gerard Guy , Yung, Godwin

Mayo Clinic

British Journal of Haematology | June 7, 2017 | Volume: 178 | Issue: 5 | Pages: 756-763

10.1111/bjh.14754 | PMID 28591409 Get It

SummaryPeripheral neuropathy (PN) is the most troublesome adverse event associated with the proteasome inhibitor bortezomib. Studies suggest an inflammatory aetiology for bortezomib‐induced PN (BiPN) and it has been hypothesized that reducing inflammation with concomitant dexamethasone may reduce BiPN incidence and/or severity. We retrospectively analysed PN rates from 32 studies (2697 patients with previously untreated multiple myeloma) incorporating bortezomib and differing dexamethasone schedules: partnered dosing (days of and after bortezomib), weekly dosing, and other dosing schedules (e.g. days 1–4, 8–11). Pooled overall PN rates were 45·5%, 63·9%, and 47·5%, respectively, with 5·3%, 11·0%, and 9·6% grade ≥3. Adjusting for potential confounders (age, gender, presence of thalidomide, bortezomib treatment duration), PN rates in patients on partnered dosing schedules appeared lower than in patients on weekly or other dosing schedules. Analyses conducted using patient‐level data suggest that cumulative dexamethasone dose, a potential confounding factor, is unlikely to have influenced the analyses. Findings were similar in a separate pooled analysis excluding data from regimens incorporating thalidomide, when pooled overall PN rates were 50·1%, 63·9%, and 48·3%, respectively, with 4·2%, 11·0%, and 8·6% grade ≥3. These findings suggest that partnered dexamethasone dosing may result in less severe BiPN compared with alternative dexamethasone dosing schedules.
Supracondylar Fracture Practice Improvement Module
Stans, Anthony A. , Martin, David , Albanese, Stephen A.

Mayo Clinic

Journal of Pediatric Orthopaedics | June 7, 2017 | Volume: 37 | Issue: 5 | Pages: e308-e308

10.1097/bpo.0000000000001040 | PMID 28594694 Get It

Consumer Perspectives on Access to Direct‐to‐Consumer Genetic Testing: Role of Demographic Factors and the Testing Experience
Gollust, Sarah E. , Gray, Stacy W. , Carere, Deanna Alexis , Koenig, Barbara A. , McGuire, Amy , Sharp, Richard R. , Spector‐Bagdady, Kayte , Wang, Na , Roberts, J. Scott , Group, for the PGen Study, Roberts, J. Scott , Lehmann, Lisa Soleymani , Green, Robert C. , Group, for the PGen Study, Sharp, Richard R , Gray, Stacy W

Mayo Clinic

The Milbank Quarterly | June 7, 2017 | Volume: 95 | Issue: 2 | Pages: 291-318

10.1111/1468-0009.12262 | PMID 28589610 Get It

Policy Points: The policy context of direct‐to‐consumer personal genomic testing (DTC‐PGT) has been evolving over the last decade, with little empirical data available about consumers’ perspectives. A majority of consumers of DTC‐PGT supported expanded access to services and their integration into the medical context and opposed more governmental regulation. Consumers’ attitudes about access to services and regulation did not vary based on the specific genetic risk information they received from companies, but may vary based on whether consumers perceived their DTC experience negatively. ContextWhile policymakers have been considering the appropriateness of direct‐to‐consumer personal genomic testing (DTC‐PGT) for more than a decade, there is little empirical data on consumers’ views regarding the regulation of these products. No research has assessed whether consumers’ personal experience with testing is related to their views about access to and regulation of DTC tests.MethodsData were analyzed from the PGen Study, a longitudinal prospective cohort of DTC‐PGT customers of 23andMe (n = 564) and Pathway Genomics (n = 377; total N = 941). Consumers were sent an electronic survey before receiving genetic test results and again 6 months after receipt of results.FindingsAt the 6‐month follow‐up, more than 80% of participants believed that people have a right to access genetic information directly, that parents should be able to get DTC‐PGT testing for their children, and that genetic information should be kept private. Participants supported health insurance coverage of PGT (60%), wider availability of PGT (68%), and inclusion of genetic information in medical records (63%). Participants were less supportive of government regulation (28%) and restricting testing to clinical settings (14%). Conservative political ideology was associated with less support for government regulation (P < 0.001), as was feeling more confident in one's genetic knowledge (P < 0.05). Participants’ level of computed genetic risk for common diseases, as indicated by their actual test results received from companies, showed no relationship with attitudes. However, those who perceived that they had received elevated risk results expressed lower support for expanded availability and incorporation of PGT into health care (P < 0.01). Those who reported being upset by their genetic test results were less likely to endorse access to DTC products without a medical professional (P < 0.01).ConclusionsPGT consumers supported expanded access to these services and opposed additional regulation. Users who had a negative personal experience with PGT testing were less supportive of expanded availability without a medical professional.
INTERIM RESULTS FROM a PHASE 1/2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH NIVOLUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY HODGKIN LYMPHOMA
Herrera, Alex F. , Moskowitz, Alison J. , Ramchandren, Radhakrishnan , Feldman, Tatyana , LaCasce, Ann S. , Ansell, Stephen M. , Moskowitz, Craig H. , Fenton, Keenan , Ogden, Carol Anne, Zhang, Q. , Kato, Kazunobu, Campbell, Mary S., Bartlett, Nancy L. , Vose, Julie M. , Taft, David R. , Advani, Ranjana H.

Mayo Clinic

Hematological Oncology | June 7, 2017 | Volume: 35 | Issue: S2 | Pages: 85-86

10.1002/hon.2437_73 Get It

NIVOLUMAB FOR RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA AFTER AUTOLOGOUS TRANSPLANT: FULL RESULTS AFTER EXTENDED FOLLOW‐UP OF THE PHASE 2 CHECKMATE 205 TRIAL
Fanale, Michelle A. , Engert, Andreas , Younes, Anas , Armand, Philippe , Ansell, Stephen M. , Timmerman, John M. , Ramchandren, Radhakrishnan , Cohen, Jonathon B. , Kato, Kazunobu, Sumbul, Anne, Zinzani, Pier Luigi , Collins, Graham P. , Boer, Jan Paul de , Kuruvilla, John , Savage, Kerry J. , Trněný, Marek , Rodig, Scott J , Shipp, Margaret Ann , Farsaci, Benedetto , Santoro, Armando

Mayo Clinic

Hematological Oncology | June 7, 2017 | Volume: 35 | Issue: S2 | Pages: 135-136

10.1002/hon.2437_124 Get It

Breast cysts rapidly enlarging with replacement of breast parenchyma and asymmetry
Al‐Hilli, Zahraa , Javed, Asma , Lemaine, Valérie, Visscher, Daniel W., Pruthi, Sandhya , Boughey, Judy C.

Mayo Clinic

The Breast Journal | June 7, 2017 | Volume: 24 | Issue: 1 | Pages: 83-85

10.1111/tbj.12839 | PMID 28590556 Get It

Optimization of anti‐pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: II. Cephalosporins and penicillins update
Zobell, Jeffery T. , Epps, Kevin , Young, David C. , Epps, Kevin L

Mayo Clinic

Pediatric Pulmonology | June 7, 2017 | Volume: 52 | Issue: 7 | Pages: 863-865

10.1002/ppul.23713 | PMID 28590594 Get It

Intraoperative Infusion of Dexmedetomidine for Prevention of Postoperative Delirium and Cognitive Dysfunction in Elderly Patients Undergoing Major Elective Noncardiac Surgery
Deiner, Stacie , Luo, Xiaodong , Lin, Hung‐Mo , Saager, Leif , Sieber, Frederick E. , Lee, Hochang B. , Sano, Mary , Group, and the Dexlirium Writing, Jankowski, Christopher J., Bergese, Sergio D. , Candiotti, Keith , Flaherty, Joseph H. , Arora, Harendra, Shander, Aryeh , Rock, Peter , Jankowski, Christopher, Sessler, Daniel I. , Group, and the Dexlirium Writing

Mayo Clinic

JAMA Surgery | June 7, 2017 | Volume: 152 | Issue: 8 | Pages: e171505

10.1001/jamasurg.2017.1505 | PMID 28593326 Get It

CXCL13 is androgen-responsive and involved in androgen induced prostate cancer cell migration and invasion
Fan, Long, Zhu, Qingyi , Zhu, Cuicui , Lu, Shan , Liu, Ping , Liu, Li , Huang, Haojie

Mayo Clinic

Oncotarget | June 7, 2017 | Volume: 8 | Issue: 32 | Pages: 53244-53261

10.18632/oncotarget.18387 | PMID 28881808 Get It